Northpond Ventures II GP, LLC bought $8.4M of CAMP
owner at Camp4 Therapeutics Corp. 763,636 shares at an average of $11.00, traded Oct 15, 2024, filed Oct 17, 2024.
Score components
- +12Role10% owner
- +25Trade size$8.4M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextMid range
- +15Cluster7 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -25.2%, 3m -59.0%, 6m -81.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025393, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | CConversion Common Stockindirect: By Northpond Ventures II, LP | +1,003,193 | - | - | 1,003,193 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Common Stockindirect: By Northpond Ventures, LP | +471,415 | - | - | 471,415 | Oct 17, 2024 |
| Oct 15, 2024 | POpen-market purchase Common Stockindirect: By Northpond Ventures III, LP | +763,636 | $11.00 | $8.4M | 763,636 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series A Prime Preferred Stockderivativeindirect: By Northpond Ventures II, LP | -11,251,624 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series B Preferred Stockderivativeindirect: By Northpond Ventures, LP | -5,287,303 | - | - | 0 | Oct 17, 2024 |
Related signals
Other insiders at Camp4 Therapeutics Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | CAMPbuy Camp4 Therapeutics Corp | Kelly Gold Chief Financial Officer | $40k 10,000 shares | - | |
| 53Moderate | Camp4 Therapeutics Corp | Andrew J. Schwab director | $1.6M 400,000 shares | -16% | |
| 23Weak | Camp4 Therapeutics Corp | Andrew J. Schwab director | $45 10 shares | -0% | |
| 46Moderate | Camp4 Therapeutics Corp | Andrew J. Schwab director | $880k 191,865 shares | -7% | |
| 43Moderate | Camp4 Therapeutics Corp | Daniel Tardiff Chief Scientific Officer | $8,273 1,738 shares | -100% | |
| 48Moderate | Camp4 Therapeutics Corp | Josh Mandel-Brehm Chief Executive Officer | $11k 6,551 shares | +2% | |
| 48Moderate | Camp4 Therapeutics Corp | Kelly Gold Chief Financial Officer | $11k 6,551 shares | +10% | |
| 48Moderate | Camp4 Therapeutics Corp | Yuri Maricich Chief Medical Officer | $11k 6,551 shares | +108% | |
| 46Moderate | Camp4 Therapeutics Corp | Richard A Young director | $27k 16,378 shares | +10% | |
| 63Notable | Camp4 Therapeutics Corp | 5AM Partners VI, LLC owner | $4.5M 2,941,176 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.